A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer
- Wiechno, P.
- Somer, B.G.
- Mellado, B.
- Chłosta, P.L.
- Cervera Grau, J.M.
- Castellano, D.
- Reuter, C.
- Stöckle, M.
- Kamradt, J.
- Pikiel, J.
- Durán, I.
- Wedel, S.
- Callies, S.
- André, V.
- Hurt, K.
- Brown, J.
- Lahn, M.
- Heinrich, B.
ISSN: 0302-2838, 1873-7560
Argitalpen urtea: 2014
Alea: 65
Zenbakia: 3
Orrialdeak: 516-520
Mota: Artikulua